CVS Up on Medicare Advantage Strength: Is It a Buy Before Q2 Earnings?

Key Takeaways CVS stock is up nearly 50% YTD, driven by strong Q1 results and rising investor confidence. The Senate dropped PBM and Medicare cuts, lifting a key overhang for CVS's Caremark and Aetna units. CVS raised 2025 EPS guidance to $6.00-$6.20 after segment-wide growth and operational efficiency.CVS Health Corporation (CVS) is gaining investor attention as the stock trends higher ahead of its second-quarter earnings release, scheduled for July 30, 2025. A key catalyst behind the recent uptick occur ...